181 related articles for article (PubMed ID: 16401163)
1. Open-label risperidone for Asperger's disorder: negative symptom spectrum response.
Rausch JL; Sirota EL; Londino DL; Johnson ME; Carr BM; Bhatia R; Miller S
J Clin Psychiatry; 2005 Dec; 66(12):1592-7. PubMed ID: 16401163
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M
J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935
[TBL] [Abstract][Full Text] [Related]
3. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
Stigler KA; Diener JT; Kohn AE; Li L; Erickson CA; Posey DJ; McDougle CJ
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):265-74. PubMed ID: 19519261
[TBL] [Abstract][Full Text] [Related]
5. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.
Hirschfeld RM; Eerdekens M; Kalali AH; Canuso CM; Khan AA; Karcher K; Palumbo JM
Int Clin Psychopharmacol; 2006 Jan; 21(1):11-20. PubMed ID: 16317312
[TBL] [Abstract][Full Text] [Related]
6. Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.
Miyaoka T; Wake R; Furuya M; Liaury K; Ieda M; Kawakami K; Tsuchie K; Inagaki T; Horiguchi J
BMC Psychiatry; 2012 Nov; 12():215. PubMed ID: 23194148
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
8. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
Anil Yağcioğlu AE; Kivircik Akdede BB; Turgut TI; Tümüklü M; Yazici MK; Alptekin K; Ertuğrul A; Jayathilake K; Göğüş A; Tunca Z; Meltzer HY
J Clin Psychiatry; 2005 Jan; 66(1):63-72. PubMed ID: 15669890
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
[TBL] [Abstract][Full Text] [Related]
10. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
[TBL] [Abstract][Full Text] [Related]
11. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
[TBL] [Abstract][Full Text] [Related]
12. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.
Alvarez E; Ciudad A; Olivares JM; Bousoño M; Gómez JC
J Clin Psychopharmacol; 2006 Jun; 26(3):238-49. PubMed ID: 16702888
[TBL] [Abstract][Full Text] [Related]
13. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Zhong KX; Sweitzer DE; Hamer RM; Lieberman JA
J Clin Psychiatry; 2006 Jul; 67(7):1093-103. PubMed ID: 16889453
[TBL] [Abstract][Full Text] [Related]
14. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
15. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
[TBL] [Abstract][Full Text] [Related]
16. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
Azorin JM; Spiegel R; Remington G; Vanelle JM; Péré JJ; Giguere M; Bourdeix I
Am J Psychiatry; 2001 Aug; 158(8):1305-13. PubMed ID: 11481167
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
18. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
[TBL] [Abstract][Full Text] [Related]
19. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
20. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.
Hirschfeld RM; Keck PE; Kramer M; Karcher K; Canuso C; Eerdekens M; Grossman F
Am J Psychiatry; 2004 Jun; 161(6):1057-65. PubMed ID: 15169694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
